close
close

Avicanna Reports Q2 2024 Page 1

Posted on by Vaseline
Avicanna Reports Q2 2024 Page 1

Q2 2024 revenue of $6.1 million, up 85% from Q2 2023
Completion of Two Real-World Evidence Trials on Epidermolysis Bullosa and Musculoskeletal Pain

TORONTO, August 14, 2024 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-based cannabinoid products, reports second quarter 2024 results.

Related Posts